Quantifying Morbidity Risk Attributed to Red‐Cell Transfusion Volume in Optimally Transfused Patients With β‐Thalassemia
- 3 October 2025
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (1) , 149-151
Abstract
In the long-term follow up study (de-LIGHT), the magnitude of transfusion burden was significantly and incrementally associated with morbidity development in transfusion-dependent patients achieving target hemoglobin thresholds.Keywords
Funding Information
- Agios Pharmaceuticals
This publication has 11 references indexed in Scilit:
- Impact of lifetime anaemia and iron control on outcomes in β‐thalassaemia: Data from the longitudinal de‐LIGHT studyBritish Journal of Haematology, 2025
- Reframing thalassaemia syndrome as a benign haematopoietic stem cell disorderBritish Journal of Haematology, 2024
- ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaBlood, 2024
- Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disordersBlood, 2024
- Anemia and iron overload as prognostic markers of outcomes in β-thalassemiaExpert Review of Hematology, 2024
- Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemiaAmerican Journal of Hematology, 2021
- Primary HBB gene mutation severity and long‐term outcomes in a global cohort of β‐thalassaemiaBritish Journal of Haematology, 2021
- Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta‐thalassemia in Taiwan: A real‐world analysisTransfusion, 2021
- Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort studyAnnals of Hematology, 2021
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaNew England Journal of Medicine, 2020